Table 4 Complications, treatments and clinical outcomes of COVID-19 patients

Clinical classification

 Mild type

10 (5.9)

5 (6.8)

5 (5.3)

0.750

 Moderate type

130 (76.9)

52 (70.3)

78 (82.1)

0.097

 Severe type

24 (14.2)

15 (20.3)

9 (9.5)

0.074

 Critical type

5 (3.0)

2 (2.7)

3 (3.2)

1.000

Severe complication

 ARDS

16 (9.5)

9 (12.2)

7 (7.4)

0.304

 Shock

2 (1.2)

2 (2.7)

0 (0)

0.190

 AKI

4 (2.4)

1 (1.4)

3 (3.2)

0.632

 MODS

3 (1.8)

1 (1.4)

2 (2.1)

1.000

Treatments

 Admitted in ICU

20 (11.8)

10 (13.5)

10 (10.5)

0.634

 Oxygen therapy

162 (95.9)

71 (95.9)

91 (95.8)

1.000

 High-flow nasal cannula oxygen therapy

14 (8.3)

7 (9.5)

7 (7.4)

0.780

 Prone Positioning

4 (2.4)

2 (2.7)

2 (2.1)

1.000

 Non-invasive positive pressure ventilation

7 (4.1)

3 (4.1)

4 (4.2)

1.000

 Invasive positive pressure ventilation

3 (1.8)

2 (2.7)

1 (1.1)

0.582

 Extracorporeal membrane oxygenation

2 (1.2)

2 (2.7)

0 (0)

0.190

 Continuous renal replacement therapy

1 (0.6)

1 (1.4)

0 (0)

0.438

 Antiviral treatment

  Monotherapy

41 (24.3)

16 (21.6)

25 (26.3)

0.588

  Combination therapy

128 (75.7)

58 (78.4)

70 (73.7)

 Antibiotic treatment

87 (51.5)

45 (60.8)

43 (44.2)

0.043

 Glucocorticoids

44 (26.0)

27 (36.5)

17 (17.9)

0.008

  Course of treatment (days) -Median (IQR)

7 (5–9)

7 (5–10)

6 (4–8.5)

 Gamma globulin

44 (26.0)

27 (36.5)

17 (17.9)

0.008

  Course of treatment (days)-Median (IQR)

6 (4–8)

6 (4–7)

6 (3.5–8.5)

Clinical outcome

 Discharged from hospital

154 (91.1)

72 (97.3)

82 (86.3)

0.002

 Death

1 (0.6)

1 (1.4)

0 (0)

 Hospitalization

14 (8.3)

1 (1.4)

13 (13.7)

  Length of hospital stay (days)

13 (11.0–18.0)

13 (11.0–17.8)

13 (10.0–19.0)

Viral clearance duration (days) ^a

 Median (IQR)

10 (8–15)

11 (8–15)

9 (7–15)

0.080